Aquestive Therapeutics, Inc. AQST Royalty Monetization
Royalty Monetization at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:DeferredTaxAssetsSaleOfFutureRevenue.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty monetization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty monetization?
- Aquestive Therapeutics, Inc. (AQST) reported royalty monetization of $16.29M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty monetization?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s royalty monetization has grown at a -1.4% compound annual growth rate (CAGR), from $16.75M to $16.29M.
- What does royalty monetization mean?
- This represents the tax impact associated with the monetization of future royalty streams or revenue rights. It captures the deferred tax consequences of selling rights to future cash flows, which often involves complex accounting for revenue recognition and tax timing differences. This metric is essential for evaluating the tax implications of capital-raising activities involving intellectual property.